Blepharitis Management

Management

Follow Up

Follow-up visits are based on the severity of symptoms and signs, current treatment and comorbid factors
Includes interval history, visual acuity measurement, external exam, slit-lamp biomicroscopy, and IOP measurement
Patients should be re-evaluated within a few weeks to determine the response to therapy and assess compliance to the treatment regimen
Prompt referral to an ophthalmologist is recommended if any of the following is observed
- Visual loss
- Moderate or severe pain
- Severe or chronic redness
- Involvement of the cornea
- Recurrent episodes
- Lack of response to treatment

Faricimab up to Q16W noninferior to aflibercept Q8W in DME and nAMD

Dr. Karl Csaky, Dr. Charles Wykoff, Dr. Jeffrey Heier, 08 Apr 2021

Intravitreal injections with anti-vascular endothelial growth factor (VEGF) agents are associated with significant treatment burden for patients with diabetic macular oedema (DME) and neovascular age-related macular degeneration (nAMD). At the Angiogenesis, Exudation, and Degeneration 2021 Virtual Congress, Dr Karl Csaky of Retina Foundation of the Southwest, Dallas, Texas, US, Dr Charles Wykoff of Retina Consultants of Texas, Houston, Texas, US, and Dr Jeffrey Heier of Ophthalmic Consultants of Boston, Boston, Massachusetts, US, presented results of four phase III trials that compared the efficacy and safety of the investigational bispecific antibody, faricimab, administered at up to Q16W dosing intervals, vs the decoy VEGF-A/placental growth factor (PIGF) receptor aflibercept at Q8W dosing intervals, in patients with retinal vascular diseases.

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia

Roshini Claire Anthony, 28 Jun 2020

Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.